Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc35215822    free
PDF from PMC    free
html from PMC    free
PDF vom PMID35215822 :   free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines #MMPMID35215822
  • Abdel-Bakky MS; Amin E; Ewees MG; Mahmoud NI; Mohammed HA; Altowayan WM; Abdellatif AAH
  • Viruses 2022[Jan]; 14 (2): ä PMID35215822show ga
  • The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is currently developing into a rapidly disseminating and an overwhelming worldwide pandemic. In severe COVID-19 cases, hypercoagulability and inflammation are two crucial complications responsible for poor prognosis and mortality. In addition, coagulation system activation and inflammation overlap and produce life-threatening complications, including coagulopathy and cytokine storm, which are associated with overproduction of cytokines and activation of the immune system; they might be a lead cause of organ damage. However, patients with severe COVID-19 who received anticoagulant therapy had lower mortality, especially with elevated D-dimer or fibrin degradation products (FDP). In this regard, the discovery of natural products with anticoagulant potential may help mitigate the numerous side effects of the available synthetic drugs. This review sheds light on blood coagulation and its impact on the complication associated with COVID-19. Furthermore, the sources of natural anticoagulants, the role of nanoparticle formulation in this outbreak, and the prevalence of thrombosis with thrombocytopenia syndrome (TTS) after COVID-19 vaccines are also reviewed. These combined data provide many research ideas related to the possibility of using these anticoagulant agents as a treatment to relieve acute symptoms of COVID-19 infection.
  • |Anticoagulants/administration & dosage/isolation & purification/*therapeutic use[MESH]
  • |Blood Coagulation[MESH]
  • |Blood Coagulation Disorders/classification/*etiology/prevention & control/virology[MESH]
  • |COVID-19 Vaccines/administration & dosage/*chemistry[MESH]
  • |COVID-19/*complications/*prevention & control[MESH]
  • |Cytokine Release Syndrome/prevention & control/virology[MESH]
  • |Humans[MESH]
  • |Inflammation/etiology/prevention & control[MESH]
  • |Nanoparticles/chemistry/*therapeutic use[MESH]
  • |SARS-CoV-2/pathogenicity[MESH]
  • |Thrombophilia/etiology[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    ä 2.14 2022